Gilead Sciences, Inc. is downgraded to Hold due to uncertainty on the Arcellx acquisition and cell therapy portfolio challenges. Read more on GILD stock here.
Zero-day exploits, AI-driven Android malware, firmware backdoors, password manager trust gaps, rising DDoS define this week’s critical cyber threats.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results